Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.62 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethyl Acetate SCHEMBL3897691 | 0.93 | ALDH1A1 (0.61) | ALDH1A1LMNAHSD17B10TRPA1MGAM | |
| Ethyl Bromo Acetate SCHEMBL27578368 | 0.88 | ALDH1A1 (0.81) | ALDH1A1LMNAHSD17B10TRPA1MGAM | |
| Ethyl Acetate SCHEMBL28214003 | 0.83 | — | — | |
| Ethyl Acetate SCHEMBL28325830 | 0.83 | — | — | |
| Ethyl Acetate SCHEMBL701114 | 0.81 | ALDH1A1 (0.70) | ALDH1A1LMNAHSD17B10TRPA1MGAM | |
| Ethyl Acetate SCHEMBL29134656 | 0.80 | ALDH1A1 (0.78) | ALDH1A1LMNAHSD17B10TRPA1MGAM | |
| Ethyl Acetate SCHEMBL28816628 | 0.80 | — | — | |
| Ethyl Acetate SCHEMBL1331990 | 0.80 | — | — | |
| Ethyl Acetate SCHEMBL1331901 | 0.80 | — | — | |
| Ethyl Acetate SCHEMBL30152067 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572781-B2 | Prodrugs for use as ophthalmic agents | UNIVERSITY OF FLORIDA (US) | 2009-08-11 | — | — | US | disclosed |
| US-7534779-B2 | a steroidal quinol that is converted to a biologically active estrogen compound via enzyme catalyzed reduction; 2-(1-adamantyl)-estra-1,3,5(10)-triene-3,17 beta -diol; estrogen receptors activator; low lipid solubility; cataract, glaucoma, conjunctivitis, diabetic retinopathy | UNIVERSITY OF FLORIDA (US) | 2009-05-19 | — | — | US | disclosed |
| US-20080119446-A1 | Prodrugs for Use as Ophthalmic Agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-05-22 | — | — | US | disclosed |
| US-20070213310-A1 | Prodrugs for Use as Ophthalmic Agents | PROKAI LASZLO | 2007-09-13 | — | — | US | disclosed |
| US-20070155711-A1 | Prodrugs for use as ophthalmic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2007-07-05 | — | — | US | disclosed |
| US-7186707-B2 | Prodrugs for use as ophthalmic agents | UNIVERSITY OF FLORIDA (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1569648-A4 | PRODRUGS FOR USE A OPHTHALMIC AGENTS | UNIV FLORIDA (US) | 2006-10-04 | — | — | EP | disclosed |
| EP-1569648-A1 | PRODRUGS FOR USE A OPHTHALMIC AGENTS | University of Florida (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040171596-A1 | Prodrugs for use as ophthalmic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2004-09-02 | — | — | US | disclosed |
| WO-2004069248-A1 | PRODRUGS FOR USE A OPHTHALMIC AGENTS | UNIVERSITY OF FLORIDA (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171596-A1 | Prodrugs for use as ophthalmic agents | CYP21A2, CYP19A1, CYP17A1 | ALDH1A1 1249/4885LMNA 2259/4885HSD17B10 177/4885 |
| US-20070155711-A1 | Prodrugs for use as ophthalmic agents | CYP19A1, CYP21A2, CYP17A1 | ALDH1A1 1540/4885LMNA 2282/4885HSD17B10 255/4885 |
| US-20080119446-A1 | Prodrugs for Use as Ophthalmic Agents | CYP21A2, CYP19A1, CYP17A1 | ALDH1A1 1317/4885LMNA 2231/4885HSD17B10 175/4885 |
| US-20070213310-A1 | Prodrugs for Use as Ophthalmic Agents | CYP21A2, CYP19A1, CYP17A1 | ALDH1A1 1249/4885LMNA 2259/4885HSD17B10 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.